CTOs on the Move

Phreesia

www.phreesia.com

 
Leading healthcare organizations choose Phreesia to revolutionize their point of service. In medical groups of all sizes, Phreesia`s flexible and scalable platform drives tangible results across administrative, financial and clinical operations so that staff can focus on providing exceptional patient care.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.phreesia.com
  • 432 Park Avenue South
    New York, NY USA 10016
  • Phone: 888.654.7473

Executives

Name Title Contact Details
Ashwin Altekar
Vice President of Information Security Profile

Similar Companies

CarePayment

Out-of-pocket healthcare expenses are on the rise, which means patients are having difficulty paying their share and providers are finding it difficult to collect from those patients. It`s a lose-lose situation. CarePayment offers a unique solution that helps patients meet their financial obligations and protect their financial health while helping providers stay financially healthy by reducing bad debt and improving cash flow.

Inland Imaging Svc

Inland Imaging Svc is a Grand Terrace, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthcare Prncipals Group

Healthcare Prncipals Group LLC is a Beaufort, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardo Medical Inc.

Cardo Medical Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Beverly Hills, CA. To find more information about Cardo Medical Inc., please visit www.cardomedical.com

StemCells

StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.